Immatics (NASDAQ:IMTXW) Short Interest Update

Immatics (NASDAQ:IMTXW) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 1,300 shares, a decrease of 13.3% from the September 15th total of 1,500 shares. Based on an average daily volume of 800 shares, the days-to-cover ratio is presently 1.6 days.

Immatics Price Performance

IMTXW traded up $0.04 during trading on Wednesday, reaching $1.20. The stock had a trading volume of 100 shares, compared to its average volume of 8,117. The stock’s 50 day moving average is $2.36 and its two-hundred day moving average is $2.68. Immatics has a one year low of $0.87 and a one year high of $4.14.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.